Effect of vitamin D therapy on bone turnover markers in postmenopausal women with osteoporosis and osteopenia

Endocrine Practice

Volumn 17, Issue 6, 2011, Pages 873-879

  Tanzy, Margaret ^a   Camacho, Pauline ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CREATININE; RISEDRONIC ACID; VITAMIN D;

ADULT; ARTICLE; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; THERAPY EFFECT; VITAMIN D DEFICIENCY;

ACADEMIC MEDICAL CENTERS; AGED; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; BONE RESORPTION; COHORT STUDIES; DIPHOSPHONATES; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HUMANS; MEDICAL RECORDS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; RETROSPECTIVE STUDIES; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84855831074     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP10339.OR     Document Type: Article

References (19)

1. Randell A, Sambrook PN, Nguyen TV, et al. Direct clini-cal and welfare costs of osteoporotic fractures in elderly men and women. Osteoporos Int. 1995;5:427-432.
2. Camacho PM, Miller PD. Osteoporosis: A Guide for Clinicians. Philadelphia, PA: Lippincott Williams & Wilkins, 2007.
3. Holick MF, Siris ES, Binkley N, et al. Prevalence of vita-min D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab. 2005;90:3215-3224. (Pubitemid 41014278)
4. Camacho PM, Dayal AS, Diaz JL, et al. Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis. J Clin Oncol. 2008;26:5380-5385.
5. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994;79: 1693-1700.
6. Garnero P Sornay-Rendu E, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 1996;11:337-349. (Pubitemid 26076383)
7. Reginster JY, Collette J, Neuprez A, Zegels B, Deroisy R, Bruyere O. Role of biochemical markers of bone turn-over as prognostic indicator of successful osteoporosis therapy. Bone. 2008;42:832-836.
8. Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res. 1996;11: 1531-1538. (Pubitemid 26331009)
9. Camacho P, Kleerekoper M. Biochemical markers of bone turnover. In: Favus M, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 6th ed. Washington, DC: American Society for Bone and Mineral Research, 2006: 127-133.
10. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB. Early changes in bio-chemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res. 1998;13:1431-1438. (Pubitemid 28418909)
11. Iwamoto J, Takeda T, Sato Y, Uzawa M. Determinants of one-year response of lumbar bone mineral density to alen-dronate treatment in elderly Japanese women with osteopo-rosis. Yonsei Med J. 2004;45:676-682. (Pubitemid 39263992)
12. Ravn P Hosking D, Thompson D, et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the Early Postmenopausal Intervention Cohort Study. J Clin Endocrinol Metab. 1999; 84:2363-2368.
13. Kim SW, Park DJ, Park KS, et al. Early changes in biochemical markers of bone turnover predict bone min-eral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis. Endocr J. 2005;52:667-674. (Pubitemid 43104669)
14. Johnson J, Dawson-Hughes B. Precision and stability of dual-energy x-ray absorptiometry measurements. Calcif Tissue Int. 1991;49:174-178.
15. Bergmann P, Body JJ, Boonen S, et al (Members of Advisory Board on Bone Markers). Evidence-based guidelines for the use of biochemical markers of bone turn-over in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract. 2009;63:19-26.
16. Sairanen S, Kärkkäinen M, Tähtelä R, et al. Bone mass and markers of bone and calcium metabolism in postmeno-pausal women treated with 1,25-dihydroxyvitamin D (cal-citriol) for four years. Calcif Tissue Int. 2000;67:122-127. (Pubitemid 30616008)
17. Hunter D, Major P, Arden N, et al. A randomized con-trolled trial of vitamin D supplementation on preventing postmenopausal bone loss and modifying bone metabo-lism using identical twin pairs. J Bone Miner Res. 2000;15: 2276-2283.
18. Ooms ME, Roos JC, Bezemer PD, van der Vijgh WJ, Bouter LM, Lips P. Prevention of bone loss by vitamin D supplementation in elderly women: a randomized double-blind trial. J Clin Endocrinol Metab. 1995;80:1052-1058.
19. Sahota O, Masud T, San P, Hosking DJ. Vitamin D insuf-fciency increases bone turnover markers and enhances bone loss at the hip in patients with established vertebral osteoporosis. Clin Endocrinol (Oxf). 1999;51:217-221. (Pubitemid 29378907)